🇺🇸 Erbitux (Cetuximab) in United States

43 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Infusion Related Reaction — 7 reports (16.28%)
  2. Dehydration — 6 reports (13.95%)
  3. Erythema — 5 reports (11.63%)
  4. Hypotension — 5 reports (11.63%)
  5. Diarrhoea — 4 reports (9.3%)
  6. Dyspnoea — 4 reports (9.3%)
  7. Blood Pressure Decreased — 3 reports (6.98%)
  8. Blood Pressure Increased — 3 reports (6.98%)
  9. Chills — 3 reports (6.98%)
  10. Pruritus — 3 reports (6.98%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Erbitux (Cetuximab) approved in United States?

Erbitux (Cetuximab) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Erbitux (Cetuximab) in United States?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.